Nevada’s psychedelic resolution signals a growing shift in national drug policy—and Arizona may be closer than ever to joining the movement for psychedelic policy reform.
Nevada may be grabbing headlines for its legislative leap into psychedelic reform, but its latest move could carry implications far beyond the state line. Earlier this year, the Nevada Senate passed Senate Joint Resolution 10 (SJR 10), a formal request for Congress to reschedule key psychedelic substances and expand federal research into their therapeutic potential.
Although the measure carries no legal weight, its intent is clear: Nevada wants the federal government to step aside and let science lead. SJR 10 represents more than a symbolic gesture—it’s an attempt to nudge national policy out of the past and into a future increasingly defined by data, not dogma.
With Arizona’s robust wellness economy, growing public interest in plant-based and alternative therapies, and a disproportionately large veteran population struggling with trauma-related conditions, it’s worth asking: Could this be our moment to join the broader wave of psychedelic policy reform?
Healing Roots and Policy Ruptures
Long before modern researchers entered the conversation, psychedelic plants and compounds were already central to healing traditions throughout the Americas. Psilocybin mushrooms, ayahuasca, peyote, and ibogaine have been used for millennia by Indigenous cultures to treat spiritual imbalance, emotional suffering, and community disconnection. Their use was structured, ceremonial, and rarely frivolous.
That context was largely erased when the Controlled Substances Act of 1970 swept most psychedelics under Schedule I—the federal government’s harshest classification. The move choked off nearly all scientific inquiry, branding psychedelics as medically useless and dangerously addictive, despite growing clinical interest at the time.
But history doesn’t stay buried forever. In recent years, countries like Canada and Switzerland have carved out exceptions for therapeutic psychedelic use—Canada, for instance, permits psilocybin treatment for patients in palliative care. Oregon created a legal framework for licensed psilocybin therapy. Colorado followed suit. Nevada is now adding its name to a list of states willing to challenge federal inertia.
Arizona, too, is poised for movement—if it has the political will to act.
The Science Says Go
Psychedelic policy reform isn’t fueled by nostalgia or anecdote—it’s being driven by cold, clinical data. Over the last two decades, researchers at institutions like Johns Hopkins, Stanford, and Yale have published dozens of peer-reviewed studies pointing to the efficacy of psychedelics in treating PTSD, anxiety, addiction, and major depressive disorder.
One MAPS-sponsored trial found that 67 percent of patients undergoing MDMA-assisted therapy for severe PTSD no longer qualified for the diagnosis after treatment. Psilocybin has been linked to reduced suicidality, improved emotional regulation, and rapid remission of depressive episodes. Ibogaine, derived from the African shrub Tabernanthe iboga, has been credited with interrupting opioid dependency and even showing signs of regenerative effects on brain tissue damaged by trauma.
It isn’t just researchers taking notice. The Food and Drug Administration has granted “Breakthrough Therapy” designation to both psilocybin and MDMA—effectively fast-tracking their development and approval processes. Meanwhile, agencies like the Department of Defense and Veterans Affairs are actively funding psychedelic research for traumatic brain injury and combat-related stress.
In Arizona, where veterans account for more than half a million residents and mental health resources are often spread thin, the potential impact of therapeutic psychedelics is not theoretical—it’s immediate and measurable.
Lessons from the Silver State
Nevada’s resolution calls for rescheduling a slate of psychedelic compounds, including psilocybin, psilocin, MDMA, DMT, mescaline, and ibogaine. This list reflects not only therapeutic potential but also the substances most likely to benefit from updated research frameworks.
The state isn’t stopping with symbolic gestures. Nevada lawmakers have also proposed a pilot program specifically targeting veterans and first responders for psychedelic-assisted therapy. If enacted, it would establish treatment protocols, track outcomes, and create a model for future integration into existing mental health systems.
Arizona has yet to introduce legislation that mirrors Nevada’s approach, but the foundation exists. State lawmakers have previously supported cannabis reform, trauma-informed care, and behavioral health alternatives. With the right coalition—clinicians, researchers, veterans groups, and patient advocates—Arizona could easily draft a pilot program of its own, especially given the bipartisan appetite for innovation in mental health treatment.
If federal policy shifts, Arizona would stand to benefit from immediate opportunities to lead.
Who Gets to Benefit?
Any meaningful psychedelic policy reform will also need to wrestle with thornier questions—access, affordability, and equity.
Without intentional safeguards, a future psychedelics industry could easily fall into the same traps as other medical monopolies: inflated prices, gatekept therapies, and exclusion of the very communities these substances once served. Indigenous groups have already voiced concern over the commercialization of ancestral medicines. Affordability barriers could also prevent working-class and uninsured Arizonans from accessing treatments shown to be life-changing.
Organizations like MAPS have begun to address these concerns head-on, advocating for open-source clinical protocols, community-based licensing, and respect for Indigenous intellectual traditions. Oregon’s psilocybin licensing model includes provisions for affordability, but many say there’s still work to be done to close the equity gap.
If Arizona chooses to follow the reform trail, it will need to ensure these treatments aren’t limited to the affluent and insured. Accessible psychedelic care must be more than a tagline—it must be part of the policy design.
The Future Is Closer Than It Looks
SJR 10 may not carry legal force, but its political significance is unmistakable. Nevada’s resolution is part of a much larger reckoning—one that calls into question not only outdated drug policy, but the deeper social assumptions that shaped it. Healing should not be criminalized. Innovation should not be stifled. And suffering should not be dismissed as a moral failure.
Congress now faces increasing pressure to reschedule psychedelics and support expanded research. If lawmakers respond, states like Arizona could rapidly deploy pilot programs, fund research partnerships, and attract investment from public and private sectors alike.
More importantly, we could offer something that’s been missing for far too long: options.
For veterans suffering silently. For patients out of options. For families navigating trauma with nowhere else to turn. Psychedelic policy reform is not a panacea, but it is a step forward. One rooted in evidence. One rooted in empathy. And one that Arizona may soon be ready to take.
***
Trap Culture is the ultimate destination for cannabis enthusiasts who want to experience the best of Arizona’s cannabis culture. Whether you are looking for the hottest cannabis-friendly events, the latest news on cannabis legalization, trends in the industry and exclusive, limited-edition products from the top brands in the market, Trap Culture has you covered. Visit our website to learn more about our events, our blog, and our store. Follow us on social media to stay updated on the latest news and promotions. Join the Trap Culture family and experience the most immersive and engaging social cannabis events in Arizona.
Follow us on social media
